California State Teachers Retirement System Has $71.07 Million Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

California State Teachers Retirement System grew its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 131,624 shares of the company’s stock after purchasing an additional 823 shares during the period. California State Teachers Retirement System owned approximately 0.16% of IDEXX Laboratories worth $71,068,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Valley National Advisers Inc. grew its stake in IDEXX Laboratories by 84.6% during the fourth quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock worth $26,000 after buying an additional 22 shares during the last quarter. Riverview Trust Co acquired a new stake in IDEXX Laboratories during the 1st quarter valued at $26,000. Crewe Advisors LLC bought a new position in IDEXX Laboratories in the 1st quarter valued at $26,000. DSM Capital Partners LLC acquired a new position in IDEXX Laboratories in the fourth quarter worth $33,000. Finally, Venturi Wealth Management LLC boosted its stake in IDEXX Laboratories by 226.3% in the fourth quarter. Venturi Wealth Management LLC now owns 62 shares of the company’s stock worth $34,000 after purchasing an additional 43 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Performance

Shares of NASDAQ:IDXX opened at $484.89 on Thursday. The company has a market capitalization of $40.05 billion, a price-to-earnings ratio of 46.09, a P/E/G ratio of 3.89 and a beta of 1.32. The firm’s 50 day simple moving average is $490.75 and its 200 day simple moving average is $515.59. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.57 and a quick ratio of 1.16. IDEXX Laboratories, Inc. has a fifty-two week low of $372.50 and a fifty-two week high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Wednesday, May 1st. The company reported $2.81 EPS for the quarter, beating analysts’ consensus estimates of $2.68 by $0.13. The business had revenue of $964.10 million during the quarter, compared to analysts’ expectations of $965.43 million. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. As a group, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 11 earnings per share for the current year.

Insider Activity at IDEXX Laboratories

In other news, Director Bruce L. Claflin sold 200 shares of the company’s stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $540.80, for a total value of $108,160.00. Following the completion of the transaction, the director now owns 161 shares in the company, valued at $87,068.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 2.11% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Stifel Nicolaus dropped their target price on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a research note on Monday, June 24th. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, July 10th. BTIG Research assumed coverage on IDEXX Laboratories in a research report on Thursday, July 25th. They issued a “buy” rating and a $580.00 price objective on the stock. Barclays lowered their target price on IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a research note on Thursday, May 2nd. Finally, Morgan Stanley cut their price target on IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 14th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $585.89.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.